AqueaTether Therapeutics

AqueaTether Therapeutics is a biotechnology company and a dedicated division of CellMosaic focused on developing next-generation antibody-drug conjugates (ADCs) and bioconjugates. The company utilizes its proprietary AqueaTether (AqT) drug delivery technology, which employs advanced hydrophilic linkers to improve the solubility, stability, and pharmacokinetics of hydrophobic drug payloads. AqueaTether offers a diverse portfolio of ADC assets for evaluation and partnership, including conjugates with payloads such as MMAE, SN38, and Exatecan. Its mission is to enhance the therapeutic index of targeted therapies, providing solutions for challenging drug delivery issues in oncology and hematology. The company operates as a service-oriented technology partner, supporting the discovery, development, and scale-up of novel conjugate drugs.